Evaluate the Use of Plastic Bags in Preventing and Treating Hypothermia in Neonates

August 19, 2013 updated by: Alicia Leadford, MD, University of Alabama at Birmingham

A Randomized Trial to Evaluate the Use of Plastic Bags in Preventing and Treating Hypothermia in Neonates in Developing Countries

The overall hypothesis is that placing infants 1000-2500 grams in plastic bags when compared to routine care will reduce the risk of hypothermia (< 36.5 degrees C) without increasing hyperthermia (> 37.5 degrees C).

Study Overview

Detailed Description

Prevention

After consent, infants with estimated gestational age between 26-36.6 weeks or with expected birth weight 1000-2500 grams will be randomized to resuscitation per standard protocol or to resuscitation per standard protocol and plastic bag. The intervention group will be placed into a plastic bag covering the body and back and top of head (excluding face) prior to drying the body's surface. Resuscitation efforts continue per standard of care. The infant will remain in the bag through the admission process until his/her axillary temp is in the range of 36.5- 37.5 degrees Celsius. At this time, the bag will be discontinued and discarded. Standard temperature control will be continued per nursery standard. Skin-to-skin contact between mother and baby is not excluded; however, the infant will remain in the plastic bag. Infant's axillary temperature will be measured per nursery standard after discontinuation of plastic bag. The control group will receive standard of care thermoregulation. Secondary measures (i.e. blood pressures, glucose levels, weight gain, observation for respiratory distress syndrome, bronchopulmonary dysplasia, pneumothorax, sepsis, seizures, intraventricular hemorrhage, necrotizing enterocolitis, pulmonary hemorrhage, and death) will be recorded in both groups.

Study Type

Interventional

Enrollment (Actual)

106

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Lusaka, Zambia
        • University Teaching Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Estimated gestational age 26-36.6 weeks or expected birth weight 1000-2500 grams.
  • Delivery in the hospital.

Exclusion Criteria:

  • Abdominal wall defect or myelomeningocele.
  • Major congenital anomaly.
  • Blistering skin disorder.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Resuscitation with plastic bag
Plastic bag will be used during and after resuscitation to assist with temperature regulation.
Infant will be resuscitated and placed in a plastic bag up to his/her neck and around the back of his head (not covering the face) in the delivery room and taken to the nursery. The infant will remain in the plastic bag until first axillary temperature remains stable at 36.5-37.5 degrees Celsius. Expected length of time approximately one hour.
Sham Comparator: Standard resuscitation- no plastic bag
Infant will be resuscitated per standard of care without being placed in a plastic bag for temperature regulation.
Infant will be resuscitated in the delivery room and taken to the nursery. The infant will be observed per unit standard until first axillary temperature remains stable at 36.5-37.5 degrees Celsius. Expected length of time approximately one hour.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Axillary temperature 36.5-37.5 degrees Celsius
Time Frame: 1-4 hours
Temperature taken per axilla for 1 minute
1-4 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood pressure
Time Frame: Duration of hospitalization-expected average of 4 weeks
Measure of extremity blood pressure per cuff taken during nursery stay.
Duration of hospitalization-expected average of 4 weeks
Blood glucose
Time Frame: Duration of hospitalization-expected average of 4 weeks
Measure of blood glucose per laboratory value taken per heelstick
Duration of hospitalization-expected average of 4 weeks
Seizure
Time Frame: Duration of hospitalization-expected average of 4 weeks
Seizure activity diagnosed by medical doctor or nurse. No electroencephalogram will be done.
Duration of hospitalization-expected average of 4 weeks
Death
Time Frame: Duration of hospitalization-expected average of 4 weeks
Cardiorespiratory failure
Duration of hospitalization-expected average of 4 weeks
Weight gain
Time Frame: Duration of hospitalization-expected average of 4 weeks
Infant will be weighed daily and rates of weight gain will be measured.
Duration of hospitalization-expected average of 4 weeks
Respiratory Distress Syndrome (RDS)
Time Frame: Duration of hospitalization-expected average of 4 weeks
Documentation of increased work of breathing, retractions, and a need for oxygen, intubation, or surfactant.
Duration of hospitalization-expected average of 4 weeks
Bronchopulmonary dysplasia (BPD)
Time Frame: 28 days after birth
Oxygen requirement at 28 days of life
28 days after birth
Pneumothorax
Time Frame: Duration of hospitalization-expected average of 4 weeks
Either chest radiograph documentation or clinical deterioration consistent with air leak
Duration of hospitalization-expected average of 4 weeks
Sepsis
Time Frame: Duration of hospitalization-expected average of 4 weeks
Culture proven or culture negative clinically treated course consistent with sepsis.
Duration of hospitalization-expected average of 4 weeks
Major brain injury
Time Frame: Duration of hospitalization-expected average of 4 weeks
Intracranial hemorrhage Grade 3-4 or periventricular leukomalacia documented on cranial ultrasound
Duration of hospitalization-expected average of 4 weeks
Necrotizing enterocolitis or intestinal perforation
Time Frame: Duration of hospitalization-expected average of 4 weeks
Documentation of pneumatosis or intestinal perforation on x ray or treatment course for clinical necrotizing enterocolitis per Bell's stage greater than one.
Duration of hospitalization-expected average of 4 weeks
Pulmonary hemorrhage
Time Frame: Duration of hospitalization-expected average of 4 weeks
Blood seen in the endotracheal tube and treated by physician.
Duration of hospitalization-expected average of 4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Alicia E Leadford, MD, University of Alabama at Birmingham

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2011

Primary Completion (Actual)

March 1, 2012

Study Completion (Actual)

December 1, 2012

Study Registration Dates

First Submitted

June 27, 2011

First Submitted That Met QC Criteria

July 26, 2011

First Posted (Estimate)

July 27, 2011

Study Record Updates

Last Update Posted (Estimate)

August 21, 2013

Last Update Submitted That Met QC Criteria

August 19, 2013

Last Verified

August 1, 2013

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UAB Neo 003

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypothermia, Newborn

Clinical Trials on Resuscitation and post resuscitation care with plastic bag

Subscribe